**About the Editors**

### **Vibhuti Agrahari**

Vibhuti Agrahari, Ph.D. is an assistant professor at the University of Oklahoma Health Sciences Center. Her laboratory focuses on therapeutic biomaterials and long-term drug delivery, and currently focused on nanoformulations development for ocular/otic diseases, supported by foundational and organizational grants. Her research work has been credited with two US patents, co-authored more than 35 peer-reviewed articles, 7 book chapters, and over 20 conference presentations. Dr. Agrahari's work was recognized with numerous research awards and honors, such as BJD Faculty Research Award (2018), SU Faculty Development Grant (2017), AAPS-NBC Biotechnology Graduate Student Symposium Award (2016 and 2015), Ronald MacQuarrie Fellowship (2015), Judith Hemberger Graduate Scholarship (2014), Scholar of Preparing Future Faculty Program of School of Graduate Studies (2014–2016), meritorious scholar of UMKC GAF Women's Council (2014–2017), and Research Fellowship by Ministry of Human Resource Development, Government of India (2005). She strongly believes in promoting academic excellence in learning environments that are inclusive of teaching, scholarship, community services, and leadership roles. She is an active member of professional organizations and served in various leadership roles, including Co-Chair and Scientific Committee Chair of 2016 Pharmaceutics Graduate Student Research Meeting; Council of Faculty—Junior Faculty Community Leadership Group, American Association of Colleges of Pharmacy (2018); Ambassador, Controlled Release Society—Young Scientists Committee (2018–2020); Member of AAPS Nomination Committee (2019), AAPS Strategic Planning Task Force (2020–2021) AAPS Horizon Planning Committee (2021–2022), and UMKC Women's Council Board of Directors (2022–2025).

#### **Prashant Kumar**

Dr. Prashant Kumar is a Scientific Assistant Director working on the development of low-cost and stable vaccine formulations to extend global access to the vaccines. He is currently working on AAV-based COVID-19, sIPV and combination vaccine, Measles and Rubella, and Shigella vaccine projects at Vaccine Analytics and Formulation Center (VAFC) at KU. Dr. Kumar's past projects include the development of live attenuated RV3-BB rotavirus, non-replicating rotavirus vaccine (NRRV), HPV, Salmonella, and Shigella vaccines. Most of his current/past projects are in phase 1 to 3 of clinical trials. Dr. Kumar's multidisciplinary background in bioprocessing, formulation development, analytical and biophysical characterization coupled with statistical design of experiments (DOE) has helped him in efficient process development, and cost minimization needed to make these projects a success. Dr. Kumar serves on the editorial board of several scientific journals and has a number of scientific papers and book chapters to his credit.
